Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31138390 | 1.00 | DGAT1 (0.36) | DGAT1MAPT | |
| SCHEMBL24224456 | 0.87 | DGAT1 (0.33) | DGAT1 | |
| SCHEMBL8306393 | 0.85 | CNOT7 (0.34) | MAPT | |
| SCHEMBL12620882 | 0.83 | ADORA2A (0.37) | DGAT1 | |
| SCHEMBL29266831 | 0.81 | DGAT1 (0.34) | DGAT1 | |
| SCHEMBL28722437 | 0.81 | TARBP2 (0.37) | DGAT1MAPT | |
| SCHEMBL20165957 | 0.80 | DGAT1 (0.37) | DGAT1MAPT | |
| SCHEMBL3267555 | 0.78 | P2RX7 (0.43) | DGAT1MAPT | |
| SCHEMBL30496451 | 0.78 | P2RX7 (0.43) | DGAT1MAPT | |
| SCHEMBL38663051 | 0.77 | PRPS1 (0.38) | DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2648517-B1 | TRICYCLIC HETEROCYCLES USEFUL AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS | MERCK SHARP & DOHME (US) | 2015-08-05 | — | — | EP | disclosed |
| US-20130261140-A1 | TRICYCLIC HETEROCYCLES USEFUL AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS | MERCK SHARP & DOHME CORP. | 2013-10-03 | — | — | US | disclosed |
| US-20130261140-A1 | TRICYCLIC HETEROCYCLES USEFUL AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS | MERCK SHARP & DOHME CORP. | 2013-10-03 | — | — | US | disclosed |
| WO-2012078448-A1 | TRICYCLIC HETEROCYCLES USEFUL AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS | SCHERING CORPORATION (US) | 2012-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130261140-A1 | TRICYCLIC HETEROCYCLES USEFUL AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS | DPP4, DPP7, DPP3 | DGAT1 2368/4885MAPT 4035/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.